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Why pH responsive NPs (Nanoparticles)? (1,2)
• Efficient delivery at a target site (avoiding 
accumulation in non target tissues)
• Lowering therapeutic dosage
• Minimizing harmful side effects 
• Long time circulation
• No recognition by P_glycoprotein (permeability 
glycoprotein) [MDR1]
• Promissing a drug carrier due to reversible surface 
charge




Heinz, H., et al. (2017). "Nanoparticle decoration with surfactants: molecular interactions, assembly, and 






















silicaNPs coated with poly(L_lysine) 
and hyaluronic acid,Iron
oxideNPs,GoldNPs coated by PEI(poly 
ethylene imine)
Surface chemical preparation (19)
Mechanisms for surface preparation  of pH sensitive 
NPs(nanoparticles) :
1_Ionizable chemical groups(polymericNPs)
 Amine,phosphoric acid , carboxylic acid 
2_Acid labile chemical bonds: stable in neutral pH but 
degraded in acidic media.
 Acetal, orthoester ,hydrazone,imine,cis aconyl bonds
3_Incorporation of CO2generating precursors:  
NAHCO3
9
Acid labile chemical bonds (19)
10Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, et al. pH-sensitive nano-systems for drug delivery in cancer 
therapy. Biotechnology advances. 2014;32(4):693-710.
Acetal group:
A carbon with two 
oxygen bonded
Protonation in acidic 
media




Gas generating pH sensitive Nanosystem (19)
 HCO3⁻+H⁺ H2CO3         H2O+CO2 bubbles
 NPs containing HCO3⁻has the potential to trigger drug 
release
 Ex:PLGA(poly lactic_co glycolic acid) hollow microsphers
 NaHCO3 incorporated in HMS(hollow microsphers) loaded 
with DOX(doxorubicin)
 NaHCO3+H⁺      CO2 bubbles in lysosomal compartments                                  
drug release
11
The other classification of NPs
12Goyal AK, Rath G, Faujdar C, Malik B. Application and Perspective of pH-Responsive Nano Drug Delivery Systems.  
Applications of Targeted Nano Drugs and Delivery Systems: Elsevier; 2019. p. 15-33.
Polymeric Nanoparticles (19,3)
• Organic nano carriers:
• Matrix composed of biodegradable of synthetic or natural 
origin(Albumin_alginate_chitosan)
• Ability in encapsulate and protect cargoes
• Respond to specific stimuli (pH)
• Water solubility,nontoxicity,stability
• Classified based on preparation method : Nanocapsule, 
Nanosphere
• Polymer based nanocarriers:








































































• The most used polymers
• Containing COOH group
• Protonation in acidic media           hydrophob
• Entrance via hydrophobic interaction(endocytosis)
• Deprotonation in basic media           hydrophil
• Known as charge reversal copolymers:
• PMAA(poly methacrylic acid): pKa=4.8         
15
Cationic polymers (19)
• The surface positive charge           cellular uptake
• Containing Amine group           binds H⁺         
• Protonation in acidic media
• Deprotonation in basic media:
• PDEAEM(polydiethylaminoethylmethacrylate):a side chain with 
ionizable tertiary amine group




• PVP(polyvinylpyrrolidone): responding to pH depends on   
deprotonation of pyridine group
• PHis(poly_L_Histidine)
• Extensively used in drug delivery
• An imidazole group           positive charge in acidic media                    
hydrophobic
• Releasing drug under pH=6.8 Protonation
Anionic/cationic polymers (14)




Saadat M, Zahednezhad F, Zakeri-Milani P, Heidari HR, Shahbazi-Mojarrad J, Valizadeh H. Drug Targeting 




















Release at acidic pHof
TME
 Nanosized synthetic 
symmetric structure
 Polyvalent








An excellent therapeutic 
carrier
a bilayer spherical self 
assembling phosphlipid
PC,PS,PG,SM
Saturated Pl with long acyl
chain impermeable
Both hydrophilic and 
hydrophobic drug can be 
loaded.
Liposomes (28)
• Targeted liposomes:(45 times higher cellular 
uptake)
 loading PEG to make it hydrophilic 
 Folate is the most loaded agent due to overexpression of its 
receptor on the tumor cells
 PEG is a barrier to intracellular delivery             loading a 




 Attaching more than one
group
 Exhibit longevity in
blood
 Specifically target the 
tumor




Advantages/disadvantages of liposomes (6)
Advantages Disadvantages
Non toxic, flexible,biocompatible, Low solubility
Reduce toxicity of the encapsulated agent Short half life
Increased efficacy and therapeutic index Undergo oxidation and hydrolysis
Bio degradable, Non immunogenic Leakage and fusion of encapsulated drug
Flexibility to couple  with ligands in active 
targeting 
Production cost is high 
25
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Gold NPs characteristics (7,22,4,10)
• Selective accumulation due to facile biomodification, bio
conjugation
• Binding to proteins,peptides via thiol
• Low toxicity rather than other metals
• High chemical stability
• Cancer diagnosis and imaging due to SPR effect
light scattering and absorbtion
• electromagnetic radiation(IR) local heat           PTT ( 
photo thermal therapy)












• < 250nm: endocytosis
• 100_120nm:CME                     designing size shrinked NPs                     
• 50_100nm:CvME
• <5.5 nm removes by renal system
 Shape: spherical due to decreasing friction





pH responsive size shrinkage (20)
Solid tumors:
Increased collagen(I,III) in 
tumor interstitial matrix
Hindering entrance of 
NP>60 programmable 
size changes
Wu W, Luo L, Wang Y, Wu Q, Dai H-B, Li J-S, et al. Endogenous pH-responsive nanoparticles with 
programmable size changes for targeted tumor therapy and imaging applications . Theranostics. 
2018;8(11):3038.
pH responsive size shrinkage (20)
32
Wu W, Luo L, Wang Y, Wu Q, Dai H-B, Li J-S, et al. Endogenous pH-responsive nanoparticles with 




 ZP(zeta potential) presents NP surface charge
 Zp is the potential difference between slipping plane and 
solution medium.
 Tumor cells have low ZP due to sialic acid and anionic 
residues,anionic glycocalyx








































































































• Machanisms for gaining surface charge:
• 1_affinity differences of two phases to electrons
• 2_ionization of surface groups
• 3_different ion absorbtion from electrolyte
35
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Saadat M, Zahednezhad F, Zakeri-Milani P, Heidari HR, Shahbazi-Mojarrad J, Valizadeh H. Drug Targeting Strategies 





















































Nanoparticles in drug delivery
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39Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, et al. pH-sensitive nano-systems for drug delivery in cancer 
therapy. Biotechnology advances. 2014;32(4):693-710.
























































• NPs  in range of 200_500nm
• Convenient,comfortable and cost effectiveness
• Using pH sensitive chitosan nanoparticles (a cationic 
polymer)
• A mucoadhesive polymer
• Insulin,calcitonin,elcotonin are the most used in oral 
delivery
41
Oral delivery  (13)
Organ:
In gastric pathway due to protonation of  NP in collapsed and 
hydrophobic style
In intestine pH             anionic polymers: carboxyl ionization 
and breakage H bond .
Designing with TA(trimethylammonium)           
Positive             attachment to mocosal layer
42






















































































































opsonization and               
phagocytosis
Increases the size to 
reduce kidney filteration
Regarded as a safeby
FDA
RES avasion
46Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based 
drug and gene delivery. Advanced drug delivery reviews. 2016;99:28-51.
The PEGylation effect on blood circulation
Active and passive targeting (2)
Tissue:(pH 5.7 to 7.8)
• Passive[EPReffect (enhanced permeability and retention)]
• vessels without basal membrane       pores in 200_2000nm
• Poor lymphatic drainage due to minimal distances between 
lymphatic endothelial cells          retention of NPs (EPR)
• Imbalance of neovascularization regulators:
Bradykinin,NO,vascular endothelial growth factor(VEGF)









































Saadat M, Zahednezhad F, Zakeri-Milani P, Heidari HR, Shahbazi-Mojarrad J, Valizadeh H. Drug Targeting Strategies Based 
on Charge Dependent Uptake of Nanoparticles into Cancer Cells. Journal of Pharmacy & Pharmaceutical Sciences. 
2019;22(1):191-220.
Enhanced EPR (enhanced permeability and retention) 
effect (14)
• Increasing blood pressure artificially by :
1. Angiotansin II
2_Nitroglycerin and other NO releasing factors
49Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future 
prospects. Bioconjugate chemistry. 2010;21(5):797-802.
Enhanced EPR effect (14)
50
Reduction of NG(nitroglycerin)
Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future 
prospects. Bioconjugate chemistry. 2010;21(5):797-802.
Ligands/receptor in active targeting  (2)
Receptor on tumor 
cell
Ligand Mechanism
CD44 (positive) HA (negative)
Elecrtostatic interaction(receptor
mediated endocytosis)














TF(negative) TF Recepeot mediated endocytosis
51
Tumor micro environment characteristics   (20,21,26)
• TME:
• Glycolysis hypoxia
• Producing Lactate+H⁺         acidic media
• Higher level of certain enzymes (MMP,PLA2)
• Spreading 10_20nm NPs into organs         eliminate by 
kidney ̓glumeruli
• Spreading >200nm taken up by MPS          accumulation in 
liver and spleen
52
MDR (multi drug resistance) challenge (2)
• MDR challenge :
• Transmembrane proteins (MDR1 or P_gp) efflux toxins and 
xenobiotic drugs 
• Blocking apoptosis pathway
• Efflux hydrophobic and positively charged drugs (DOX and 
Paclitaxel) (PCNPs)




How to overcome MDR?
1_gene delivery by MDR silencing agents such as SiRNA : 
• NPs with positive charge containing DOX and SiRNA
• SiRNA as an inhibitor for MRP1(the gene correlative to 
MDR)
• ZP(+4mv )using liposomes. size500nm
Internalization by endocytosis and bypass P_gp
2_drug delivery by CNP( charged Nanoparticles) to overcome 
MDR:
• Overcoming by anionic particles 
• ZP(-3mv) size100 nm
54
55
Saadat M, Zahednezhad F, Zakeri-Milani P, Heidari HR, Shahbazi-Mojarrad J, 
Valizadeh H. Drug Targeting Strategies Based on Charge Dependent Uptake of 
Nanoparticles into Cancer Cells. Journal of Pharmacy & Pharmaceutical Sciences. 
2019;22(1):191-220.




 PCNPs(positively charged Nanoparticles) entrapped in 
endosomes
 Interaction between anionic phospholipid with cationic 
polymers.
 Buffering the endosomal lumen by efflux of counter ions

















































H⁺ sponge effect  (16)
58
A.Visualization of gold nano particles byTEM.adapted with permission©2010AmericanChemical society.   B. 
VisualizationofPEI-particlesbyTEMaselectron-densespots PEI-particles areseen associated with the endosomal
membrane,leading to membrane damage. ©2002, with permission from Elsevier. C)TEM-visualization of 
superparamagnetic ironoxide nanoparticles.Adapted from permission©2010JohnWiley&Sons,
Martens TF, Remaut K, Demeester J, De Smedt SC, Braeckmans K. Intracellular delivery of nanomaterials: how to 
catch endosomal escape in the act. Nano Today. 2014;9(3):344-64.
Barriers and strategies to improve penetration of 
NPs (24)
1. Major barrier:Densed ECM due to collagen and 
LOX(lysyl oxidase)
• Cross link and stiffens the ECM
2. Composed of charged matrix polymers (collagen, 
hyaluronan)=no entrance of charged NPs
3. Elevated IFP (interstitial fluid pressure)due to high 
permeability and impaired lymphatic function
59




 Over expression of MMP2 (tuning  the size)=PEGylated
gelatin NP
 Light : a composition of lipid and spiropyran(SP)   UV   






FIGURE 2(a) Schematic depiction of themultistage nanoparticle (NP) drug deliverysystem QDGelNPs. The initial 100-
nmmultistage NP delivery system accumulatespreferentially around leaky vessels in tumortissue. Because of its large size, the 
100-nmNP cannot penetrate the dense collagen matrixof the interstitial space. However, endogenousmatrix metalloproteinases
can proteolyticallydegrade the gelatin core of the 100-nm NP,releasing smaller 10-nm NPs from its surface,which can 
penetrate deep into the tumorbecause of their small size and PEGylatedsurface.Reprinted with permission from Wonget al. 

































































































Barriers and strategies to improve penetration of 
NPs (24)
Acidity triggers degradation of acid labile linker ,ionization of 
chemical structure
EX: icluster(acidity responsive clustered NP) 
62
Zhang YR, Lin R, Li HJ, He Wl, Du JZ, Wang J . Strategies to improve tumor penetration of nanomedicines through nanoparticle 
design. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2019;11(1):e1519.
Barriers and strategies to improve penetration of 
NPs (24)
2_conjugating ECM degrading enzymes on NPs
EX: Bromelanin cojugated mesoporous silica nano carrier 
(Br_MSN)
hyaluronidase(PH20)(recombinant human hyaluronidase) on the 
surface of PLGA_PEG
3_coupling tumor penetrating peptide(iRGD:Arg,Gly,Asp)
63







































































































Nanocarrier based drugs (23)
system structure Examples of compounds
Polymeric nanoparticles
(polymer drug conjugate)
Drugs are conjugated to 
the side chain of a linear 






















Nanocarrier based drugs (25)
68
DTX: is used in the first 
line of treatment in 
breast cancer 
HEP_CA_TOC(DTX)  
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